Research programme: cancer therapeutics - Cellectar/Pierre Fabre

Drug Profile

Research programme: cancer therapeutics - Cellectar/Pierre Fabre

Latest Information Update: 29 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cellectar Biosciences; Pierre Fabre
  • Developer Cellectar Biosciences
  • Class Drug conjugates; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 27 Mar 2018 Cellectar Biosciences has patent protection for Phospholipid-ether analogs in USA
  • 16 Dec 2015 Cellectar Biosciences and Pierre Fabre enter into collaboration to discover and develop Cancer therapeutics
  • 16 Dec 2015 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top